Assessment of the safety and kinetics of IQNLF.
Recruiting
- Conditions
- IQNLF is a human antibody which can help in overcoming inhalation antrhax. Anthrax is caused by exposure to Bacillus anthracis, a spore forming bacterium. The infection can be lethal, especially when the spores are inhaled.
- Registration Number
- NL-OMON20298
- Lead Sponsor
- IQ TherapeuticsRozenburglaan 13a9727 DL GroningenThe Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
1. Male or female subjects;
2. Aged between 18 and 55;
Exclusion Criteria
1. History of any (investigational) anthrax therapy;
2. Excessive alcohol consumption;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability of intravenous administered IQNLF in healthy subjects.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics, pharmacodynamics and immunogenticity of intravenous administered IQNLF in healthy subjects.